Starpharma (ASX: SPL, OTCQX: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, today announces that it has received a $5.5M Research and Development (R&D) Tax Incentive refund for the 2024 financial year. The refund is associated with eligible R&D activities across Starpharma’s portfolio, including the company’s DEP® drug delivery programs and VIRALEZE™.

Starpharma, an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, today releases its annual report and full-year financial results for the year ended 30 June 2024.

Starpharma (ASX: SPL, OTCQX: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, today releases its Appendix 4G, Key Disclosures to Corporate Governance Principles and Recommendations, and Corporate Governance Statement, in accordance with ASX Listing Rules 4.7.3 and 4.10.3.

Starpharma (ASX: SPL, OTCQX: SPHRY), dedicated to helping patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology, today releases its Quarterly Activities Report and Appendix 4C for the period ended 30 June 2024 (Q4 FY24).

Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® radiotheranostics scientific poster presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada, overnight. The scientific poster presents data from Starpharma’s DEP® HER2 radiotheranostics program, demonstrating the promising utility of DEP® dendrimers in precision radiotheranostics for cancer imaging and therapeutic applications.

Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® irinotecan presentation delivered at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, US. The presentation was part of a rapid oral abstract session and highlighted the final results of the DEP® irinotecan Phase 1/2 clinical trial, which were reported in full last week.

Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® cabazitaxel presentation that was delivered at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, US. The presentation was part of an oral abstract session showcasing the final results of the DEP® cabazitaxel Phase 1/2 clinical trial.

Starpharma announces the full results of the Phase 2 open-label clinical trial of DEP® irinotecan. The trial met its objectives, with endpoints demonstrating positive anti-tumour efficacy of DEP® irinotecan in heavily pre-treated patients with a range of difficult-to-treat, advanced, metastatic cancers, including colorectal cancer (CRC) and platinum-resistant ovarian cancer.

Starpharma hosted an investor webinar on Wednesday, 22 May 2024, to provide shareholders with a business update. 

Starpharma (ASX: SPL, OTCQX: SPHRY), dedicated to helping patients with significant illness, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology, is pleased to provide shareholders with a business update following an extensive review of strategy and operations, led by Starpharma’s CEO, Cheryl Maley, alongside the leadership team and Board of Directors.